| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
The specific molecular targets of methyl 2,4-dihydroxybenzoate have not been fully characterized. As a phenolic compound, it may interact with various enzymes and proteins through hydrogen bonding and hydrophobic interactions. Phenolic compounds are known to have antioxidant activity through free radical scavenging and may modulate various signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, methyl 2,4-dihydroxybenzoate may exhibit antioxidant activity through its phenolic hydroxyl groups, which can scavenge free radicals. It may also demonstrate antimicrobial activity against various microorganisms. However, specific activity data for this compound are limited in the published literature.
|
| ln Vivo |
In vivo activity data for methyl 2,4-dihydroxybenzoate are not available in the published literature. As a phenolic compound, it would be expected to be metabolized and excreted following systemic exposure, but specific pharmacological effects have not been reported.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for methyl 2,4-dihydroxybenzoate would depend on the specific biological activity being investigated. Antioxidant activity could be assessed using DPPH or ABTS radical scavenging assays. Antimicrobial activity could be assessed using disc diffusion or broth microdilution methods.
|
| Cell Assay |
Cellular assays for methyl 2,4-dihydroxybenzoate would be performed using appropriate cell lines depending on the biological activity being investigated. Cells would be cultured in appropriate media and treated with compound at various concentrations for 24-72 hours.
|
| Animal Protocol |
In vivo animal studies for methyl 2,4-dihydroxybenzoate are not documented in the published literature. The compound has not been studied in animal models for therapeutic applications.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for methyl 2,4-dihydroxybenzoate are not available. As a small phenolic ester, the compound would be expected to be absorbed and metabolized through hydrolysis and conjugation reactions.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for methyl 2,4-dihydroxybenzoate are limited. As a phenolic compound, it should be handled with standard laboratory safety precautions. The compound is not approved for human therapeutic use.
|
| References |
[1]. N. S. Novikova, et al. Synthesis of Mesomorphic Derivatives of Methyl 2,4-Dihydroxybenzoate and Spectral and Luminescence Properties of Their Lanthanide Complexes. Russ J Gen Chem 88, 2564–2571 (2018).
|
| Additional Infomation |
Reports indicate that methyl 2,4-dihydroxybenzoate has been found in kudzu (Pueraria montana var. lobata) and Maclura tricuspidata, and relevant data are available for reference.
Methyl 2,4-dihydroxybenzoate is a phenolic ester used as a chemical intermediate and in research applications. It may exhibit antioxidant and antimicrobial activities characteristic of phenolic compounds. The compound is not approved for clinical use. |
| Molecular Formula |
C8H8O4
|
|---|---|
| Molecular Weight |
168.15
|
| Exact Mass |
168.042
|
| CAS # |
2150-47-2
|
| PubChem CID |
16523
|
| Appearance |
White to pink solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
352.0±12.0 °C at 760 mmHg
|
| Melting Point |
118-121 °C(lit.)
|
| Flash Point |
148.8±13.1 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
1.92
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
168
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C(C1C([H])=C([H])C(=C([H])C=1O[H])O[H])=O
|
| InChi Key |
IIFCLXHRIYTHPV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H8O4/c1-12-8(11)6-3-2-5(9)4-7(6)10/h2-4,9-10H,1H3
|
| Chemical Name |
methyl 2,4-dihydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9471 mL | 29.7354 mL | 59.4707 mL | |
| 5 mM | 1.1894 mL | 5.9471 mL | 11.8941 mL | |
| 10 mM | 0.5947 mL | 2.9735 mL | 5.9471 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
